1.Gaulard P, de Leval L.Pathology of peripheral T-cell lymphomas: where do we stand?Semin Hematol 2014;51(1):5-16
2.Jaffe ES, Harris NL, Stein H, Isaacson PG.Classification of lymphoid neoplasms: the microscope as a tool for disease discovery.Blood 2008;112(12):4384-99
3.Laribi K, Alani M, Truong C, Baugier de Materre A.Recent Advances in the Treatment of Peripheral T-Cell Lymphoma.Oncologist 2018;23(9):1039-53
4.Gallamini A, Stelitano C, Calvi R, Bellei M,Mattei D ,Vitolo U,et al.Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.Blood 2004;103(7):2474-9
5.Vose J M . International peripheral T-cell lymphoma (PTCL) clinical and pathologic review project: Poor outcome by prognostic indices and lack of efficacy with anthracyclines[J]. Blood 2005; 106(11):239A.
6.Gutierrez-Garcia G, Garcia-Herrera A, Cardesa T, Martínez A, Villamor N, Ghita G,et al.Comparison of four prognostic scores in peripheral T-cell lymphoma.Ann Oncol 2011;22(2):397-404
7. Xu P , Yu D , Wang L , Shen Z, Zhao W. Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients. Ann Hematol, 2015;94(2):239-247.
8.Guo B , Tan X , Ke Q ,Cen H. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis[J]. Plos One, 2019;14(1):e0210224.
9.International Non-Hodgkin's Lymphoma Prognostic Factors P.A predictive model for aggressive non-Hodgkin's lymphoma.N Engl J Med1993;329(14):987-94
10.Meignan M,Sasanelli M,Casasnovas RO,Luminari S,Fioroni F,Coriani C,et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging 2014; 41: 1113–1122.
11.Cottereau AS, Becker S, Broussais F, Casasnovas O, Kanoun S, Roques M,et al.Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).Ann Oncol 2016;27(4):719-24
12.Mehta-Shah N, Ito K, Bantilan K, Moskowitz AJ, Sauter C, Horwitz SM, et al.Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma.Blood Adv 2019;3(2):187-97
13.Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi YE,et al.Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.J Clin Oncol 2005;23(21):4643-51
14.Hutchings M, Loft A, Hansen M, Ralfkiaer E, Specht L.Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake.Hematol Oncol 2006;24(3):146-50
15.Feeney J, Horwitz S, Gonen M, Schoder H.Characterization of T-cell lymphomas by FDG PET/CT.AJR Am J Roentgenol 2010;195(2):333-40
16.Gurion R, Bernstine H, Domachevsky L,Michelson C, Raanani P, Vidal L,et al.Utility of PET-CT for Evaluation of Patients With Peripheral T-cell Lymphoma.Clin Lymphoma Myeloma Leuk 2018;18(10):687-91
17.Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD,Jaffe ES , MacLennan KA ,et al.Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011;117(12):3402-8
18.Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E,et al.Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score.J Clin Oncol 2006;24(16):2472-9
19.Vose J, Armitage J, Weisenburger D, International TCLP.International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.J Clin Oncol 2008;26(25):4124-30
20.Schmitz N, Trumper L, Ziepert M,Nickelsen M, Ho AD, Metzner B, et al.Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.Blood 2010;116(18):3418-25
21.O.Tournilhac, R.Delarue, P.Gaulard. Peripheral T-cell lymphomas. Blood Rev 2007; 21(4):201-216.
22.Rudiger T, Weisenburger DD, Anderson JR, Armitage JO,Diebold J, MacLennan KA,et al.Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.Ann Oncol 2002;13(1):140-9
23.Shagera QA, Cheon GJ, Koh Y, Yoo MY, Kang KW, Lee DS,et al.Prognostic value of metabolic tumour volume on baseline (18)F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI.Eur J Nucl Med Mol Imaging 2019;46(7):1417-27
24.Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S,et al.Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.J Clin Oncol 2016;34(30):3618-26
25.Song MK, Chung JS, Shin HJ, Moon JH, Ahn JS, Lee HS,et al.Clinical value of metabolic tumor volume by PET/CT in extranodal natural killer/T cell lymphoma.Leuk Res 2013;37(1):58-63
26.Song MK, Yang DH, Lee GW, Lim SN, Shin S, Pak KJ,et al.High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.Leuk Res 2016;42:1-6
27.Ilyas H, Mikhaeel NG, Dunn JT, Rahman F, Møller H, Smith D,et al.Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma.Eur J Nucl Med Mol Imaging 2018;45(7):1142-54
28.Zhou Y, Zhang X, Qin H, Zhao Z, Li J, Zhang B,et al.Prognostic Values of Baseline (18)F-FDG PET/CT in Patients with Peripheral T-Cell Lymphoma.Biomed Res Int 2020;2020:9746716
29.Xia J, Zhu HY, Liang JH,Ding CY,Wang L,Wu W,et al.The prognostic role of 18F-FDG PET/CT baseline quantitative metabolic parameters in peripheral T-cell lymphoma.J Cancer 2019;10(23):5805-11